NVCR - DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 18 2023 in NovoCure Lawsuit - NVCR

NEW YORK, NY / ACCESSWIRE / July 10, 2023 / Levi & Korsinsky, LLP notifies investors in NovoCure Limited ("NovoCure" or the "Company") (NASDAQ:NVCR) of a class action securities lawsuit.

The lawsuit on behalf of NovoCure investors has been commenced in the United States District Court for the Southern District of New York. Affected investors purchased or otherwise acquired certain NovoCure Limited securities between January 5, 2023 and June 5, 2023. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/novocure-lawsuit-submission-form?prid=41954&wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

NovoCure Limited NEWS - NVCR NEWS

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the Company concealed the true nature of the LUNAR study data, including that the study relied on a relatively small percentage of study participants that had been receiving standard of care therapy; (ii) as a result, the data was materially less reliable in terms of demonstrating clinical efficacy; (iii) the foregoing, once revealed, was reasonably likely to have a material negative impact on the Company's regulatory prospects and operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in NovoCure during the relevant timeframe, you have until August 18, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://zlk.com/pslra-1/novocure-lawsuit-submission-form?prid=41954&wire=1 or call 212-363-7500 to discuss the case.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 4th Floor Suite #427
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP